SCHEMBL31048201

SCHEMBL31048201

O=C(O)CC(=O)Cc1ccc(F)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.44
SIGMAR1 Q99720 2/20 0.44
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
KCNQ2 O43526 1/20 0.42
KDM4E B2RXH2 3/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 2/20 0.40
RGS12 O14924 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
NFKB1 P19838 1/20 0.40
APEX1 P27695 1/20 0.40
THPO P40225 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6864288 0.86 CES2 (0.46) MAPK8SIGMAR1MAOAMAOBKCNQ2
SCHEMBL31048273 0.84 PIK3CA (0.52) KDM4EMAPTALDH1A1TSHR
SCHEMBL31048328 0.84 FAAH (0.43) MAOAMAOBKDM4EMAPTHPGD
SCHEMBL154429 0.84 KDM4E (0.55) MAPK8MAOAMAOBKDM4EMAPT
SCHEMBL23869535 0.79 RIPK1 (0.46) MAPK8SIGMAR1MAOAMAOBKCNQ2
SCHEMBL28501277 0.79 MAPK8 (0.42) MAPK8SIGMAR1MAOAMAOBKCNQ2
SCHEMBL12731507 0.79 MAPK8 (0.42) MAPK8SIGMAR1MAOAMAOBKCNQ2
SCHEMBL7821355 0.79 GAA (0.53) KDM4EALDH1A1KMT2ALMNAPOLB
Hydrochloric Acid SCHEMBL1221724 0.78 MAPK8 (0.44) MAPK8SIGMAR1MAOAMAOBKCNQ2
SCHEMBL9508267 0.77 ALDH1A1 (0.50) MAPK8SIGMAR1MAOAMAOBKCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS INC (US) 2025-11-13 US disclosed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-09-11 US disclosed
US-20250179093-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-06-05 US disclosed
WO-2025064542-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2025-03-27 WO disclosed
WO-2024178304-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179093-A1 KRAS MODULATORS KRAS, NRAS, HRAS MAPK8 526/4885SIGMAR1 4726/4885MAOA 4884/4885
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS MAPK8 513/4885SIGMAR1 4821/4885MAOA 4824/4885
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS MAPK8 513/4885SIGMAR1 4821/4885MAOA 4824/4885
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS MAPK8 513/4885SIGMAR1 4821/4885MAOA 4824/4885
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS MAPK8 772/4885SIGMAR1 908/4885MAOA 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.